Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

GE Capital serves as sole lender to Mitralign for $5 million senior secured credit facility

GE Capital, Healthcare Financial Services announced today that it served as agent and sole lender to Mitralign, Inc. for a $5 million senior secured credit facility. Mitralign will use the credit facility for working capital as the company advances development of its mitral valve repair device.

19 Jul 2010

First Edition: July 19, 2010

Today's headlines include the latest news regarding the politics of implementing health reform as well as developments from the international AIDS conference now underway in Vienna.

19 Jul 2010

MD Buyline identifies top emerging technologies with highest impact

This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.

15 Jul 2010

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing and review the supplemental New Drug Application for SPRYCEL (dasatinib) for the treatment of adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.

12 Jul 2010

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.

7 Jul 2010

First analyses on impact of Medicare Part D presented at UMB's 2010 Academy/Health Annual Meeting

Some of the first analyses on the impact of Medicare Part D, as well as new insights on drug adherence patterns by chronic disease patients, will be presented today and tomorrow at the 2010 Academy/Health Annual Meeting by several University of Maryland, Baltimore teams of pharmaceutical health services researchers.

1 Jul 2010

Response Biomedical signs subscription agreement for C$8 million private placement

Response Biomedical Corporation announced today the signing of a subscription agreement providing for the sale of C$8 million of its common shares to funds affiliated with OrbiMed Advisors, LLC. The closing of the private placement is subject to receipt of all necessary regulatory approvals, including the approval of the Toronto Stock Exchange and the shareholders of the Company.

29 Jun 2010

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

Merck and Cardiome Pharma Corp. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing approval for BRINAVESS® (vernakalant), an investigational intravenous (IV) formulation for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.

28 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

Cell>Point announced today that it has submitted to the Food and Drug Administration an Investigational New Drug (IND) application for a Phase 1b/2 trial of its 99mTc-EC-G diagnostic in assessing patients with Coronary Artery Disease (CAD).

23 Jun 2010

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.

21 Jun 2010

New public service advertisements to spread preventive medical testing awareness

Men are 24 percent less likely than women to have visited the doctor within the past year, according to new data released today by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality. In addition, men are about 30 percent more likely than women to be hospitalized for preventable conditions such as congestive heart failure and complications from diabetes, according to new AHRQ data.

16 Jun 2010

Caregiver's guide on avoiding life-threatening swallowing problems

That's the message of Drs. Roya Sayadi and Joel Herskowitz. They are a wife-husband team from Natick, Massachusetts, who are spreading the word that swallowing problems are everywhere - and they can be deadly!

10 Jun 2010

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).

9 Jun 2010

Researchers compare effectiveness of IB and AMP in high-risk patients

Major amputation is often selected over infrainguinal bypass in patients with severe systemic comorbidities because of a presumed decrease in risk of perioperative morbidity and mortality. To investigate this presumption, researchers from the Division of Vascular and Endovascular Surgery at the Brigham and Women's Hospital in Boston undertook a risk-adjusted comparison of early postoperative morbidity and mortality of high-risk patients undergoing infrainguinal bypass and major amputation.

9 Jun 2010

Preoperative BB usage to help prevent POMI revealed at Vascular Annual Meeting

A regional quality improvement effort aimed at increasing the use of preoperative beta-blocker usage to help prevent postoperative myocardial infarction was revealed today at the 64th Vascular Annual Meeting presented by the Society for Vascular Surgery.

9 Jun 2010

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

VIVUS, Inc. today announced that data from a previously reported phase 2 study evaluating the safety and efficacy of the investigational drug Qnexa for the treatment of obstructive sleep apnea were presented at SLEEP 2010, the 24th Annual Meeting of the Associated Professional Sleep Societies.

8 Jun 2010

Medicare bidding program will lead to 'suicide bidding', says Pennsylvania Association of Medical Suppliers

Providers of home medical equipment and services across Pennsylvania are proposing a fiscally responsible alternative to the mislabeled "competitive" bidding scheme currently under way in Medicare that will actually discourage competition, reduce access to care for many of Pennsylvania's more than two million Medicare beneficiaries, and put hundreds of Pennsylvania's homecare providers out of business.

8 Jun 2010

Community-based health promotion program reduces heart disease, stroke in seniors: Researcher

A community-based health promotion program delivered by over 500 peer volunteers significantly reduces heart disease and stroke in seniors, Canadian Stroke Network researcher Dr. Janusz Kaczorowski told the Canadian Stroke Congress today.

8 Jun 2010

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.

7 Jun 2010

Congestive Heart Failure News and Research

GE Capital serves as sole lender to Mitralign for $5 million senior secured credit facility

First Edition: July 19, 2010

MD Buyline identifies top emerging technologies with highest impact

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

First analyses on impact of Medicare Part D presented at UMB's 2010 Academy/Health Annual Meeting

Response Biomedical signs subscription agreement for C$8 million private placement

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

New public service advertisements to spread preventive medical testing awareness

Caregiver's guide on avoiding life-threatening swallowing problems

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Researchers compare effectiveness of IB and AMP in high-risk patients

Preoperative BB usage to help prevent POMI revealed at Vascular Annual Meeting

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

Medicare bidding program will lead to 'suicide bidding', says Pennsylvania Association of Medical Suppliers

Community-based health promotion program reduces heart disease, stroke in seniors: Researcher

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News